These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 20515613)

  • 1. Inactivation of the p53 tumor suppressor gene and activation of the Ras oncogene: cooperative events in tumorigenesis.
    Solomon H; Brosh R; Buganim Y; Rotter V
    Discov Med; 2010 May; 9(48):448-54. PubMed ID: 20515613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines.
    Lehman TA; Bennett WP; Metcalf RA; Welsh JA; Ecker J; Modali RV; Ullrich S; Romano JW; Appella E; Testa JR
    Cancer Res; 1991 Aug; 51(15):4090-6. PubMed ID: 1855224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The cooperation between p53 and Ras in tumorigenesis].
    Wei YY; Hou J; Tang WR; Luo Y
    Yi Chuan; 2012 Dec; 34(12):1513-21. PubMed ID: 23262097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mouse model for tumor progression of lung cancer in ras and p53 transgenic mice.
    Wang Y; Zhang Z; Lubet RA; You M
    Oncogene; 2006 Feb; 25(8):1277-80. PubMed ID: 16247444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
    Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
    J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant point mutation of tumor suppressor gene p53 and oncogene c-N-ras in malignant neuroendocrine pancreatic tumor.
    Hrasćan R; Pavelić K; Pavicić D; Krizanac S; Stajcer-Sittić V; Pecur L; Spaventi S; Klimpfinger M; Pavelić J
    Anticancer Res; 1996; 16(6B):3761-6. PubMed ID: 9042254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ha-Ras(G12V) induces senescence in primary and immortalized human esophageal keratinocytes with p53 dysfunction.
    Takaoka M; Harada H; Deramaudt TB; Oyama K; Andl CD; Johnstone CN; Rhoades B; Enders GH; Opitz OG; Nakagawa H
    Oncogene; 2004 Sep; 23(40):6760-8. PubMed ID: 15273725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cancer mutations and normal cell regulation].
    Fredholm BB
    Lakartidningen; 1992 Oct; 89(43):3568, 3571-2. PubMed ID: 1460965
    [No Abstract]   [Full Text] [Related]  

  • 9. K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study.
    Slebos RJ; Hoppin JA; Tolbert PE; Holly EA; Brock JW; Zhang RH; Bracci PM; Foley J; Stockton P; McGregor LM; Flake GP; Taylor JA
    Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1223-32. PubMed ID: 11097231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53: balancing tumour suppression and implications for the clinic.
    Buganim Y; Rotter V
    Eur J Cancer; 2009 Sep; 45 Suppl 1():217-34. PubMed ID: 19775621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogene activation in esophageal cancer.
    Casson AG; Mukhopadhyay T; Cleary KR; Ro JY; Levin B; Roth JA
    J Thorac Cardiovasc Surg; 1991 Nov; 102(5):707-9. PubMed ID: 1943188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers.
    Akkiprik M; Ataizi-Celikel C; Düşünceli F; Sönmez O; Gulluoglu BM; Sav A; Ozer A
    J Gastrointestin Liver Dis; 2007 Mar; 16(1):11-7. PubMed ID: 17410283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ki-ras codon 12 point and P53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer.
    Yamaguchi K; Chijiiwa K; Torato N; Kinoshita M; Tanaka M
    Am J Gastroenterol; 2000 Aug; 95(8):1939-45. PubMed ID: 10950039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 Attenuates the oncogenic Ras-induced epithelial-mesenchymal transition in human mammary epithelial cells.
    Zhang J; Lei Y; Gao X; Liang Q; Li L; Feng J; Hou P; Han L; Zhang Y; Huang B; Lu J
    Biochem Biophys Res Commun; 2013 May; 434(3):606-13. PubMed ID: 23583409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The properties of p53 proteins selected for the loss of suppression of transformation.
    Olson DC; Levine AJ
    Cell Growth Differ; 1994 Jan; 5(1):61-71. PubMed ID: 8123594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. K-ras, p53 mutations, and microsatellite instability (MSI) in gallbladder cancer.
    Saetta AA
    J Surg Oncol; 2006 Jun; 93(8):644-9. PubMed ID: 16724348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor suppressor p53 restricts Ras stimulation of RhoA and cancer cell motility.
    Xia M; Land H
    Nat Struct Mol Biol; 2007 Mar; 14(3):215-23. PubMed ID: 17310253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant p53: an oncogenic transcription factor.
    Strano S; Dell'Orso S; Di Agostino S; Fontemaggi G; Sacchi A; Blandino G
    Oncogene; 2007 Apr; 26(15):2212-9. PubMed ID: 17401430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Detection of P53 and K-ras gene mutations in lung cancer with oligonucleotide chip].
    Liu JB; Xie JP; Zou ZL; Chen LJ; Li LY; Wang SQ
    Sheng Wu Gong Cheng Xue Bao; 2002 Jul; 18(4):447-51. PubMed ID: 12385241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways.
    Lax SF; Kendall B; Tashiro H; Slebos RJ; Hedrick L
    Cancer; 2000 Feb; 88(4):814-24. PubMed ID: 10679651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.